Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence
Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AnastrozoleElacestrant+3
Italy- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:Stemline Therapeutics Inc.












